In this interview, trade knowledgeable Dr. Lohit Khera discusses the evolving position of microRNA in analysis, diagnostics, and precision drugs. He additionally highlights the most recent RNA extraction and evaluation improvements and the way these superior applied sciences deal with key challenges in small RNA analysis.
What initially sparked the scientific curiosity in microRNA, and the way has that focus developed over the previous decade?
The discovery that microRNAs (miRNAs) regulate gene expression post-transcriptionally was a paradigm shift, and their position in developmental biology and most cancers caught researchers’ consideration globally.
Over the final decade, the sector has exploded with biomarker discovery from liquid biopsy samples, diagnostics, and even therapeutics, the place researchers are designing miRNA mimics and inhibitors. It is turning into a translational science, with sturdy trade and scientific ties.
What makes microRNA such a robust goal in present organic and biomedical analysis?
MicroRNAs have a uncommon leverage as a result of they act like molecular switches that fine-tune complete gene networks; they may or won’t be particular to single genes. They are additionally secure in biofluids, making them excellent candidates for non-invasive diagnostics from liquid biopsy samples. Their tissue- and disease-specific expression patterns present specificity, and optimized miRNA extraction kits carry ease of use and sensitivity, which is exactly what researchers need of their biomarker or therapeutic targets.
Why is the flexibility to isolate all sizes of RNA—particularly microRNA—so important for researchers as we speak?
Small RNAs are notoriously tough to seize with conventional kits that favor longer transcripts, however their useful significance is large. Many labs would possibly miss out on crucial knowledge as a result of their extraction strategies are usually not optimized for “actual” complete RNA restoration. Whether for focused microRNA expression profiling or performing sequencing, you want high-quality microRNA in applicable concentrations. This ensures reproducibility and accuracy, particularly when working with low-input like biofluids or degraded samples like FFPE tissue.
What are the largest challenges researchers face when working with small RNA, and the way are these being addressed by rising applied sciences?
Low abundance and contaminating background noise are persistent hurdles. Small RNAs are sometimes misplaced throughout extraction resulting from low abundance and the widespread extraction applied sciences affected by inherent bias towards massive nucleic acids. Although higher binding chemistries and ultra-low enter kits promise higher extraction, they must rely on both utilizing massive service RNA or sturdy chemical substances that may finally make their manner into the ultimate eluted RNA and intrude with downstream purposes. Silicon carbide is a revolutionary resin that may seize small RNA with out the necessity for service RNA or undesirable chemical substances.
Background noise is one other prevalent challenge that is extra regarding for NGS-based downstream purposes. This background noise makes use of up essential reagents throughout small RNA sequencing and impacts the genome-mapped reads and miRNA mapping. Norgen has just lately launched the EXTRAClean equipment, which eliminates this challenge, considerably enhancing the output from small RNA sequencing.
Can you share the story behind Norgen Biotek Corp.’s founding and the issue it initially got down to remedy in RNA analysis?
Norgen Biotek was based by Dr. Yosef Haj-Ahmad, a scientist with a mission to develop and manufacture revolutionary nucleic acid (NA) purification kits, particularly from advanced samples like serum or FFPE tissue. The core challenge was yield and integrity for small NAs like exosomal RNA and cell-free DNA (cfDNA). We needed to develop a platform that delivered constant, high-quality small RNAs throughout all fragment sizes all the way down to 20-25-nucleotide-long miRNAs. Our silicon carbide-based expertise was born out of that want. It is now utilized by researchers who can not afford to lose sign resulting from partial restoration.
Image Credit: Norgen Biotek Corp.
Norgen has developed its distinctive silicon carbide-based expertise for RNA isolation. How does this method examine to extra conventional silica-based strategies?
Silicon carbide has a broader binding profile than silica, notably for low molecular weight nucleic acids. This means we will retain lengthy and small RNAs and RNA with high and low GC content material with excessive effectivity. Traditional silica columns are inclined to favor longer and high-GC-content transcripts and should underrepresent microRNAs or fragmented RNAs. Our method gives higher consistency, notably for advanced or low-input samples.
Image Credit: Norgen Biotek Corp.
What are a number of the most promising purposes of microRNA in fields like oncology, agriculture, or diagnostics?
In oncology, circulating microRNAs are transforming how we detect and monitor cancers. They supply real-time snapshots of tumor burden and remedy response.
In agriculture, plant microRNAs are being explored to enhance crop resilience and illness resistance. Diagnostic purposes like salivary microRNAs for oral cancers or urinary microRNAs for kidney illness are additionally booming.
How is microRNA used to drive innovation in non-invasive or minimally invasive diagnostics?
MicroRNAs are perfect for liquid biopsies—they are often remoted from plasma (blood), urine, and saliva, and their expression patterns change with illness state. This makes them good for early detection and monitoring without having tissue biopsies. We are seeing diagnostic panels emerge for cancers, cardiovascular circumstances, and even neurodegenerative ailments. Some corporations are even combining microRNA profiles with machine studying to reinforce predictive energy. It is a leap towards accessible, non-invasive diagnostics that can be utilized in routine screening.
As demand grows for precision drugs, how do you see RNA—particularly small RNA—shaping the way forward for customized remedy?
Small RNAs have gotten the molecular fingerprints of illness. Their potential to replicate dynamic physiological states makes them extremely helpful for tailoring remedies. For instance, microRNA signatures may also help stratify sufferers and predict therapeutic response in most cancers. As we combine multi-omics into precision drugs, microRNA profiling gives a complementary layer that bridges gene expression with scientific phenotype. I feel within the close to future, we’ll see increasingly inclusion of microRNA-informed therapeutic choices.
The final two Nobel Prizes in physiology have spotlighted RNA-based discoveries—what does that say about the way forward for this subject?
It underscores RNA’s central position in biology and drugs. From figuring out miRNA a few years in the past to the current influence of modified mRNA for the COVID-19 vaccine, the Nobel wins replicate a long time of foundational work lastly bearing fruit. This validation is serving to to extend funding, innovation, and public curiosity. RNA is now not only a messenger, it is a software, a therapeutic, and a diagnostic molecule. The way forward for biomedicine could have RNA on the centre.
How do you envision the position of automation and AI in the way forward for RNA extraction and evaluation?
Automation is key to consistency, particularly as labs scale up testing or function in regulated environments. We are seeing extra demand for pre-filled, automation-ready kits and scalable protocols for various volumes of liquid biopsy samples. Meanwhile, AI is transforming knowledge interpretation from microRNA-based diagnostics, the place expression patterns will be refined. Machine studying algorithms can detect clinically related patterns involving many various miRNAs which are simple to overlook with conventional strategies. Together, automation and AI speed up discovery whereas minimizing human error, making RNA workflows extra environment friendly and reproducible.
About Dr. Lohit Khera 
Dr. Khera is the Head of Scientific Sales at Norgen Biotek. With greater than 10 years of expertise in most cancers analysis and molecular biology from prestigious establishments just like the Weizmann Institute of Science and LSU Health Science Center, Dr. Khera is devoted to advancing international most cancers analysis and diagnostics by way of cutting-edge applied sciences.